Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. Fibronostics, a global ...
Neurotronic, Inc., a developer of multi-organ denervation to treat complex cardiovascular and metabolic disease, announced that the first clinical outcom...
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter Neurosciences, Inc , a clinical...
Protaryx Medical, an innovative medical device company developing disruptive access solutions for minimally invasive left-heart procedures, announced tha...
First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure -Pulse Biosciences, ...
This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot fla...
Resilience is no longer a corporate slogan — it’s the new currency of survival in biopharma. As the sector races between scientific breakthroug...
-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, celebrates the...
Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, EVerGel, in 2026, and will enhance its...
Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundat...
Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in ...
Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
© 2026 Biopharma Boardroom. All Rights Reserved.
